{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:14:25Z","timestamp":1793481265048,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.numecd.2013.04.016","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T09:45:35Z","timestamp":1373276735000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone"],"prefix":"10.1016","volume":"24","author":[{"given":"A.","family":"Mazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fruci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Guzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"D'Orrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Malaguarnera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.numecd.2013.04.016_bib1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.numecd.2013.04.016_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.numecd.2013.04.016_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.numecd.2013.04.016_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0015-0282(99)00383-0","article-title":"Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study","volume":"72","author":"Azziz","year":"1999","journal-title":"Fertil Steril"},{"issue":"7","key":"10.1016\/j.numecd.2013.04.016_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0002-9378(81)90746-8","article-title":"Hirsutism: implications, etiology, and management","volume":"140","author":"Hatch","year":"1981","journal-title":"Am J Obstet Gynecol"},{"issue":"16","key":"10.1016\/j.numecd.2013.04.016_bib6","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.numecd.2013.04.016_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0015-0282(16)45254-4","article-title":"Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females","volume":"35","author":"Mathur","year":"1981","journal-title":"Fertil Steril"},{"issue":"7","key":"10.1016\/j.numecd.2013.04.016_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.numecd.2013.04.016_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2013.04.016_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/jc.2005-1329","article-title":"Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome","volume":"91","author":"Ehrmann","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.numecd.2013.04.016_bib11","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/humrep\/der088","article-title":"The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk","volume":"26","author":"Amato","year":"2011","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.numecd.2013.04.016_bib12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/jc.2007-2429","article-title":"Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials","volume":"93","author":"Cosma","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"7421","key":"10.1016\/j.numecd.2013.04.016_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","article-title":"Metformin in polycystic ovary syndrome: systematic review and meta-analysis","volume":"327","author":"Lord","year":"2003","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.numecd.2013.04.016_bib14","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1093\/humrep\/deh440","article-title":"Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome","volume":"19","author":"Kashyap","year":"2004","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.numecd.2013.04.016_bib15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.fertnstert.2010.12.002","article-title":"The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study","volume":"95","author":"Ladson","year":"2011","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.numecd.2013.04.016_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.fertnstert.2004.02.104","article-title":"A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and\/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study","volume":"82","author":"Hoeger","year":"2004","journal-title":"Fertil Steril"},{"issue":"7","key":"10.1016\/j.numecd.2013.04.016_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1471-0528.2006.00966.x","article-title":"The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome \u2013 a randomised, double-blind, placebo-controlled trial","volume":"113","author":"Lord","year":"2006","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.numecd.2013.04.016_bib18","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2005-1994","article-title":"Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial","volume":"91","author":"Eisenhardt","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.numecd.2013.04.016_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/09513590903215581","article-title":"Clinical, metabolic, and endocrine parameters in response to\u00a0metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial","volume":"26","author":"Otta","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"10.1016\/j.numecd.2013.04.016_bib20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/humrep\/del025","article-title":"The use of metformin for women with PCOS undergoing IVF treatment","volume":"21","author":"Tang","year":"2006","journal-title":"Hum Reprod"},{"issue":"8","key":"10.1016\/j.numecd.2013.04.016_bib21","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","article-title":"Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome","volume":"85","author":"Pasquali","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.numecd.2013.04.016_bib22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1345\/aph.1G025","article-title":"Spironolactone for hirsutism in polycystic ovary syndrome","volume":"39","author":"Christy","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.numecd.2013.04.016_bib23","article-title":"Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome","volume":"Mar 28","author":"Kebapcilar","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.numecd.2013.04.016_bib24","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","volume":"2","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.numecd.2013.04.016_bib25","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","volume":"4","author":"Farquhar","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.numecd.2013.04.016_bib26","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study","volume":"89","author":"Ganie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.numecd.2013.04.016_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12325-008-0039-5","article-title":"Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol\/cyproterone acetate in the treatment of hirsutism: a randomised controlled study","volume":"25","author":"Karakurt","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.numecd.2013.04.016_bib28","first-page":"CD002249","article-title":"Clomiphene and anti-oestrogens for ovulation induction in PCOS","volume":"4","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.numecd.2013.04.016_bib29","first-page":"89","article-title":"Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"765","key":"10.1016\/j.numecd.2013.04.016_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/pgmj.65.765.459","article-title":"Lack of effect of spironolactone on hair shaft diameter in hirsute females","volume":"65","author":"McLellan","year":"1989","journal-title":"Postgrad Med J"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947531300118X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947531300118X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T14:53:39Z","timestamp":1539528819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093947531300118X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S093947531300118X"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2013.04.016","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2013.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}